{
    "organizations": [],
    "uuid": "39bc5f7c89b88bb768d29930b0aa5fc77155213d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ssy-group-sees-fy-profit-attributa/brief-ssy-group-sees-fy-profit-attributable-up-in-range-of-30-pct-to-40-pct-idUSFWN1QH0JQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Ssy Group Sees FY ‍Profit Attributable Up In Range Of 30 Pct To 40 Pct",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Ssy Group Ltd:\n* ‍PROFIT ATTRIBUTABLE FOR YEAR ENDED 31 DECEMBER 2017 IS EXPECTED TO INCREASE SIGNIFICANTLY RANGING FROM 30% TO 40%​\n* EXPECTED RESULT DUE TO ‍ INCREASES IN SALES VOLUME AND AVERAGE SELLING PRICE OF INTRAVENOUS INFUSION SOLUTIONS​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-27T17:44:00.000+02:00",
    "crawled": "2018-02-28T13:01:16.031+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "ssy",
        "group",
        "ltd",
        "attributable",
        "year",
        "ended",
        "december",
        "expected",
        "increase",
        "significantly",
        "ranging",
        "expected",
        "result",
        "due",
        "increase",
        "sale",
        "volume",
        "average",
        "selling",
        "price",
        "intravenous",
        "infusion",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}